Press Releases May 4, 2026 08:30 AM

RESEARCH FRONTIERS TO HOST FIRST QUARTER 2026 CONFERENCE CALL

Research Frontiers to release Q1 2026 financials and host conference call discussing results and recent developments

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
REFR

Research Frontiers Inc., a Nasdaq-listed technology company specializing in SPD-Smart light-control film technology, announced it will release its Q1 2026 financial results on May 7, 2026, followed by a conference call led by its CEO Joseph M. Harary to discuss financial and operating results as well as recent company developments.

RESEARCH FRONTIERS TO HOST FIRST QUARTER 2026 CONFERENCE CALL
REFR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The company will release its Q1 2026 financial results and host a conference call on May 7, 2026.
  • Research Frontiers develops and licenses SPD-Smart light-control film technology used in vehicles, buildings, and other applications.
  • The technology is licensed to major chemical, material science, and glass companies, impacting automotive, aerospace, construction, and materials sectors.

WOODBURY, NY, May 04, 2026 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced today that it will release its first quarter 2026 financial results on Thursday, May 7, 2026. Research Frontiers will also host a conference call at 4:30 p.m. Eastern Time on Thursday, May 7, 2026 to discuss its first quarter 2026 financial and operating results, as well as recent developments.

  • Who: Joseph M. Harary, President & CEO

  • Date/Time: Thursday, May 7, 2026, 4:30 PM ET

  • Dial-in Information: 1-888-334-5785

  • Conference Link: https://join.broaddata.com/?id=research-frontiers

  • Questions: Email to Questions@SmartGlass.com

  • Replay: Available on Friday, May 8, 2026 for 90 days at https://smartglass-ir.com/

About Research Frontiers

Research Frontiers (Nasdaq: REFR) is a publicly traded technology company and the developer of patented SPD-Smart light-control film technology which allows users to instantly, precisely and uniformly control the shading of glass or plastic products, either manually or automatically. Research Frontiers has licensed its smart glass technology to numerous companies that include well known chemical, material science and glass companies. Products using Research Frontiers’ smart glass technology are being used in tens of thousands of cars, aircraft, yachts, trains, homes, offices, museums and other buildings. For more information, please visit our website at www.SmartGlass.com, and on Facebook, Twitter, LinkedIn and YouTube.

Note: From time to time Research Frontiers may issue forward-looking statements which involve risks and uncertainties. This press release contains forward-looking statements. Actual results, especially those reliant on activities by third parties, could differ and are not guaranteed. Any forward-looking statements should be considered accordingly. “SPD-Smart” and “SPD-SmartGlass” are trademarks of Research Frontiers Inc.

CONTACT
Joseph M. Harary
President and CEO
Research Frontiers Inc.
 +1-516-364-1902
Info@SmartGlass.com


Risks

  • Financial results depend on activities by third parties, introducing uncertainty in revenue recognition.
  • Forward-looking statements suggest potential variability in performance and market acceptance of technology.
  • Licensing agreements and adoption rates in various industries could affect revenue and growth prospects.

More from Press Releases

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Jun 14, 2026 Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026